News

Published on 8 Sep 2021 on Zacks via Yahoo Finance

Axsome (AXSM) Up 11.7% Since Last Earnings Report: Can It Continue?


Article preview image

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM). Shares have added about 11.7% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Axsome due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

Axsome's Q2 Earnings Beat Estimates, Revenues Nil

NASDAQ.AXSM price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday? - Axsome Therapeutics...

Monday, Axsome Therapeutics Inc AXSM released data from the SYMPHONY Phase 3 trial of AXS-12 (reb...

Benzinga 25 Mar 2024

Narcolepsy patients report high symptom persistence By Investing.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a company focused on developing therapies for central...

Investing.com 25 Mar 2024

AXS-12 shows promise in narcolepsy treatment, trial finds By Investing.com

Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company, announced today...

Investing.com 25 Mar 2024

Axsome Triumphs Over Major Depressive Disorder With Auvelity

Axsome Therapeutics Inc. (NASDAQ:AXSM) is a fast-growing pharmaceutical company headquartered in ...

GuruFocus.com via Yahoo Finance 22 Mar 2024

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

It was a busy week for the biotech sector with lots of study data readouts and regulatory approva...

Zacks via Yahoo Finance 21 Mar 2024

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Axsome Therapeutics, Inc. AXSM announced that it has dosed the first patient in the phase III PAR...

Zacks via Yahoo Finance 20 Mar 2024

Axsome commences phase 3 trial for depression drug By Investing.com

Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company focused on developin...

Investing.com 19 Mar 2024

Axsome therapeutics director sells over $2.2m in company stock By Investing.com

In a recent move, Roger Jeffs, a director at Axsome Therapeutics, Inc. (NASDAQ:AXSM), sold a...

Investing.com 15 Mar 2024

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

Axsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth qua...

Zacks via Yahoo Finance 21 Feb 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript February 20, 2024 Axsome...

Insider Monkey via Yahoo Finance 21 Feb 2024